Aeson® US EFS/Pivotal Study

About Carmat

Carmat is a pioneering medical device company developing the Aeson® system, a fully artificial heart intended as a bridge-to-transplant for patients with end-stage biventricular heart failure. The device is unique in its use of biocompatible materials and biomimetic design to replicate the natural heart's function and reduce anticoagulation therapy. Having received CE Mark approval in Europe and undergoing an FDA-approved Early Feasibility Study in the U.S., the company is navigating the complex path to commercialization in a high-stakes, capital-intensive market. Its success hinges on clinical data, reimbursement strategies, and scaling manufacturing.

Therapeutic Areas